• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MyInsights
  • Strategy-Consulting
  • Contact Us
Select Page

Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review

by | Oct 7, 2024 | Publications

Imaging Sci Dent. 2024 Sep;54(3):221-231. doi: 10.5624/isd.20240032. Epub 2024 Jul 17. ABSTRACT PURPOSE: Multiple myeloma (MM) is a rare cancer that is typically managed with bisphosphonates to slow bone resorption and prevent skeletal complications. This study aimed...

Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review

by | Oct 6, 2024 | Publications

Crit Rev Oncol Hematol. 2024 Oct 3:104529. doi: 10.1016/j.critrevonc.2024.104529. Online ahead of print. ABSTRACT PURPOSE: Many clinical trials of therapeutic interventions for multiple myeloma do not use patient important outcomes and rely on the use of surrogate...

Immunoglobulin D-Lambda Multiple Myeloma Initially Presenting in the Sphenoid Sinus, Orbital Apex, and Skull Base: A Systematic Review with a Case Report

by | Oct 2, 2024 | Publications

J Neurol Surg Rep. 2024 Sep 16;85(3):e144-e155. doi: 10.1055/s-0044-1790589. eCollection 2024 Jul. ABSTRACT Objectives Multiple myeloma (MM) with initial manifestations in the sphenoid sinus, orbital apex, and skull base is exceedingly rare. A systematic review was...

Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis

by | Oct 1, 2024 | Publications

Blood Adv. 2024 Sep 30:bloodadvances.2024014139. doi: 10.1182/bloodadvances.2024014139. Online ahead of print. ABSTRACT Quadruplet regimens (anti-CD38 monoclonal antibodies (mAbs) with proteosome inhibitor (PI) and immunomodulatory (IMID) drugs) are increasingly being...

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria

by | Sep 24, 2024 | Publications

Leuk Lymphoma. 2024 Sep 24:1-10. doi: 10.1080/10428194.2024.2395440. Online ahead of print. ABSTRACT Patients with certain subsets of multiple myeloma continue to have poor outcomes and are in need of novel treatment approaches. Strict eligibility criteria for...

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

by | Sep 18, 2024 | Publications

PLoS One. 2024 Sep 6;19(9):e0308463. doi: 10.1371/journal.pone.0308463. eCollection 2024. ABSTRACT INTRODUCTION: Patients with multiple myeloma (MM) face heightened infection susceptibility, particularly severe risks from COVID-19. This study, the first systematic...
« Older Entries

Recent Content

  • Ninlaro Combo Delays Post-Transplant Progression in Relapsed Myeloma
  • Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells
  • Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma
  • Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
  • Imaging aspects of maxillomandibular bone alterations in patients with multiple myeloma treated with bisphosphonates: A systematic review
  • Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review
  • Transplant in myeloma: individualized approaches needed depending on context, access and biology
  • FDA Receives Application to Review D-VRd in Multiple Myeloma Subset
  • Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor
  • Understanding Multiple Myeloma Symptoms
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT